ADMA

#1975
ADMA Biologics Inc - Common Stock
9.3 4 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
9.34
9.34
Intervallo Annuale
7.21
20.46
Variazione giornaliera
-1.48%
Variazione Mensile
+8.73%
Variazione di 6 mesi
-40.51%
Variazione Annuale
-45.35%
Chiusura Precedente
9.4 8
Open
9.3 4
Minimo
9.3 4
Massimo
9.3 4
Volume
178
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
ADMA BIOLOGICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K

ADMA BIOLOGICS, INC. current report, Q4 FY2024

Full document

ADMA Biologics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Form 8-K was filed by ADMA Biologics, Inc. on November 21, 2024, reporting events that occurred on November 19, 2024. The filing addresses significant changes to the composition of the Company's Board of Directors and committee memberships.

Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a current report regarding corporate governance changes.

Material Changes

  • Resignation: Bryant E. Fong resigned effective immediately as a member of the Board of Directors and all associated committees (Audit, Governance and Nominations, and Compensation). Mr. Fong served on the Board since 2012 and was the Chairman of the Audit Committee.
  • Reason for Departure: Mr. Fong resigned to devote more time to his roles as Managing Director of Biomark Capital Fund and Partner/Co-Portfolio Manager of Stonepine Capital Management. The filing states there are no disagreements between Mr. Fong and the Company regarding operations, policies, or practices.
  • Appointments:
    • Young T. Kwon, PhD, was appointed as Chairman of the Audit Committee and designated as an "audit committee financial expert."
    • Steven A. Elms was added as a member of the Audit Committee.
    • Alison C. Finger was added as a member of the Governance and Nominations Committee and the Compensation Committee.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.

Key Facts for Investor Verification

  • Verify the new composition of the Audit Committee, specifically the appointment of Young T. Kwon, PhD, as Chairman and financial expert.
  • Confirm the effective date of Bryant E. Fong's resignation (November 19, 2024) and the absence of any stated disputes.
  • Review the updated committee memberships for Steven A. Elms and Alison C. Finger to assess governance continuity.

Notizie